Imatinib Dr. Reddy’s

Imatinib, the active ingredient in Imatinib Dr. Reddy's, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients with BCR-ABL positive disease.

GNH USA supplies Imatinib Dr. Reddy's as a licensed, GDP-compliant international pharmaceutical supplier, delivering EU‑approved quality to hospitals, oncology centres, pharmacies and clinics worldwide. The company ensures consistent batch release, robust handling, and compliance with global import regulations.

Imatinib is a targeted therapy that inhibits specific tyrosine kinases involved in certain cancers.

- Chronic Myeloid Leukemia (CML): Reduces leukemic cell proliferation and improves survival in patients with BCR‑ABL positive disease. - Gastrointestinal Stromal Tumor (GIST): Blocks c‑KIT and PDGFR signaling, leading to tumor shrinkage and disease control in adults.

Imatinib may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Edema - Fatigue

Serious or Rare Side Effects: - Severe neutropenia or leukopenia - Hepatotoxicity (elevated liver enzymes, hepatitis) - Cardiac dysfunction (e.g., reduced left‑ventricular ejection fraction) - Pulmonary arterial hypertension

Before and during treatment, several safety measures should be observed.

- Monitor blood counts: Perform regular complete blood count to detect neutropenia. - Assess liver function: Check hepatic enzymes before and during therapy. - Evaluate cardiac status: Baseline and periodic echocardiograms for patients at risk. - Avoid in patients with known hypersensitivity: Discontinue if a severe allergic reaction occurs. - Pregnancy and lactation: Use only if the benefit outweighs the risk; safety not established. - Store at room temperature: Keep below 25 °C, in the original container, protected from moisture and light.

Imatinib can interact with several medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): May increase imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): May reduce therapeutic levels. - Antacids containing aluminum or magnesium: Can decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): May modestly raise plasma concentrations. - Moderate CYP3A4 inducers (e.g., carbamazepine, phenobarbital): May lower drug exposure. - Warfarin: Imatinib can enhance anticoagulant effect, requiring INR monitoring.